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Abstract: A recent clinical trial proved that autologous olfactory mucosal cell (OMC) 
transplantation improved locomotion in dogs with naturally occurring spinal injuries 
comparable to human lesions. However, not all dogs responded to the treatment, likely due to 
the transplantation procedures involving injections of cell suspensions that are associated with 
cell death, uneven cell distribution and cell washout. Encapsulating cells in protective 
hydrogel matrices offers a tissue engineering solution to safely achieve 3-D growth of viable 
transplant cells for implantation into injury sites, to improve regenerative outcomes. We show 
for the first time that canine OMCs can be propagated with high viability in 3-D collagen 
matrices. Further, we describe a method to incorporate canine OMCs pre-labelled with 
clinical grade iron-oxide nanoparticles into the constructs. Intra-construct labelled cells could 
be visualised using magnetic resonance imaging, offering substantial promise for in vivo 
tracking of cOMCs delivered in protective matrices. 
 
 




Spinal cord injury (SCI) has high associated costs for healthcare systems,[1] with a critical 
need to investigate emerging therapies. Cell therapy using olfactory mucosal cells (OMCs; a 
mixture of olfactory ensheathing cells [OECs] and olfactory fibroblasts) can promote axonal 
regeneration following SCI[2,3] and offers an autologous, low-risk cell source, with limited 
ethical and immunological implications.[4,5] In a 2012 trial in domestic canines with chronic 
naturally occurring SCI, autologous transplantation of canine OMCs (cOMCs) could restore 
locomotor coordination between thoracic/pelvic limbs.[6] OMCs have also been safety tested 
in human trials, with no recorded adverse events one year after transplantation.[7,8]  
 
In the canine trial, only 12/23 dogs responded to transplantation demonstrating the need to 
refine OMC therapy for improved regenerative potential.[6] Low cell survival using standard 
injection of cell suspensions is likely a major factor in poor functional outcomes; <5% of 
injected neural progenitor cells and ca. 29% of oligodendrocyte precursors survive 
transplantation procedures.[9,10] In rodents,  OMC survival was only 3.1 ± 1.4% three weeks 
post-transplantation.[11] Hydrogels may offer a protective cell delivery solution, possessing 
tissue-mimetic mechanical properties that confer biocompatibility and allow survival/3-D cell 
growth in a mouldable matrix[12]- hydrogels offer better transplant survival and distribution in 
injury sites.[10,13] Rodent OMCs have been successfully cultured in hydrogel matrices,[14,15] 
with OMCs and Matrigel constructs able to support neurite outgrowth in vitro.[15]  
 
A major requirement for cell therapy translation is non-invasive cell tracking post-
transplantation to correlate cell biodistribution with functional/safety outcomes. Extensive 
progress has been made in non-invasive tracking of suspensions of cells,[16] but this is 
overwhelmingly overlooked for cells encapsulated in implantable matrices. However, 
hydrogel delivery of transplant cells poses a unique set of considerations for cell tracking. 
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These include the ability of contrast agents to track cells in biomaterials with various 
physicochemical properties, immune cell infiltration into biomaterials and possible 
accumulation of signalling agent in immune cells (leading to false positives) and how cell 
division and subsequent dilution of signalling agent is affected by encapsulation. One study 
proved that neonatal rat astrocytes could be safely labelled with magnetic nanoparticles 
(MNPs), incorporated into collagen hydrogels and imaged using magnetic resonance imaging 
(MRI) up to 14 days, demonstrating the translational potential of this approach.[17] To our 
knowledge, this is the only example of cell specific tracking after their encapsulation into 
biomaterials using non-invasive methods. It is crucial therefore to test and refine such an 
imaging approach for clinical cells and materials. In this report, we describe the first 
combination of these two bioengineering technolgies for clinical transplant cell populations. 
Accordingly, we demonstrate safe and homogenous 3-D encapsulation of cOMCs in type I 
collagen hydrogel matrices is feasible and that clinical grade nanoparticles combined with 
MRI can be used to detect ‘intra-construct’ cOMCs.  
 
2. Experimental Section 
Expanded methods are in Supplementary Information. Briefly, cells preserved during the 
Cambridge cOMC transplantation trial[6] were used here. Cells were mixed with collagen 
before setting to form 3-D cultures. cOMC labelling was achieved by incubation (24 h) with 5 
µg/mL Lumirem (siloxane based, clinical contrast MNPs) before trypsinisation and 
encapsulation in collagen. 
 
Cells were immunostained with p75 (OECs) and Fn (fibroblasts) and morphologically 
characterised to classify their relative proportions, as previously described.[18] Nuclear 
staining, LIVE/DEAD staining and the Click-iT® EdU assay were performed to quantify cell 
numbers, viable cells and proliferation respectively. Perl’s staining was used to detect MNPs 
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in neutral red counterstained cells. All images and z-stacks of live/fixed cell-constructs were 
acquired using an Axio Observer Z.1. Quantification was performed from regularly spaced 
planes of analysis (PoA) of a minimum of three z-stacks from each gel/experiment. Coronal 
MRI sections were obtained using a Bruker 9.4 T Avance III HD instrument. 
 
Data were analysed by one-way ANOVA with Bonferroni’s multiple comparison test or an 
unpaired t-test as appropriate using Prism (Graphpad, San Diego). Data are presented as mean 
± standard error of the mean. ‘n’, refers to the number of independent cultures used, each 




3.1. cOMCs can be safely incorporated and distributed throughout collagen hydrogels  
Microscopy of cOMCs grown on glass showed healthy cells, displaying normal attachment 
and morphologies associated with a mixed population of cells (Figures 1A&B). p75 positive, 
bi-polar cells identified as canine OECs (cOECs) made up 50.0 ± 2.9% and Fn positive, 
rounded cells identified as fibroblasts made up 22.2 ± 6.9% of the population (Figure 1B). 
27.8 ± 4.8% cells did not fit either category and were unclassified. This proportion of cOECs 
correlates well with our previous study (47.6 ± 3.1%)[18] and the reported cOEC densities used 
for the clinical trial for which these cells were derived  (49 ± 6.8%).[6] Following 
incorporation into collagen, the majority (≳ 95%) of cells expressed a fusiform morphology 
and were p75 positive, with a small proportion (< 5%) remaining unstained or displaying a 
rounded morphology (Figures 1C&D; Supplementary Video 1). Collagen densities of 1.2 
and 2.4 mg/mL could support 3-D cOMC growth with a mean gel depth of 1133 μm (range: 
885-1434 μm) (Figures 1C&D). At all gel densities and timepoints, cell number was greater at 
the base versus the rest of the matrix. However, there was no statistically detectable difference 
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between cell numbers within the remainder of the gel (Figure 1E&F; Supplementary Video 
2). LIVE/DEAD staining indicated high cell viability (> ca 85%) across all experimental 
conditions (Figure 2A&C; Supplementary Videos 3&4). EdU positive cells were clearly 
visible within the matrix with no statistical differences in proliferation profiles across all 
experimental conditions (Figures 2B&D). 
 
3.2. MNP labelled cOMCs can be visualised in 3-D hydrogels using histology and MRI 
techniques 
Successful pre-labelling of cOMCs was achieved on glass with cells displaying blue 
accumulations indicative of MNP presence 24 h post labelling, absent in controls (Figures 
3A&B). Labelled cells displayed similar morphology and adherence to controls, with cell 
number/viability unaffected by MNP labelling (Figures 3C&D). Hydrogel incorporated, 
labelled cells displayed elongated morphologies similar to those on glass. MNPs were 
detected by Perl’s staining and 90.9 ± 1.3% intraconstruct cOMCs were labelled (Figure 3E; 
Supplementary Video 5). Extracellular MNPs were detected (Supplementary Video 5), 
however, the majority (ca. > 95%) appeared to be intracellular. Gels containing unlabelled 
cOMCs showed a weak increase in signal intensity versus agarose. By contrast, gels 
containing labelled cells displayed intense and discreet spots of hypointense contrast 





We show for the first time that a clinical transplant population can be safely and effectively 
labelled with clinically approved MNPs, grown throughout collagen matrices and 
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subsequently imaged non-invasively. Our results support the feasibility of developing a 
mouldable, implantable “plug” of  cOMCs encapsulated in a protective matrix and not subject 
to lysis and clumping during injection.[19] Moreover, cell survival and distribution in the 
matrix can be verified ex vivo before surgical procedures. As MNP labelling of transplant 
cells has significant clinical potential as a safe method to facilitate MRI tracking,[16] adaption 
of these simple yet effective techniques to other clinical cell populations (including human 
cells) seems feasible and warrants further investigation.  
 
The key parameters for feasibility evaluation of hydrogel encapsulation were cell safety and 
capacity of gels to maintain cells in 3-D conformations. For clinical injury, cOMCs are 
cultured for up to four days pre-transplantation[6], justifying our time-points to ensure that 
cells survive the requisite time in the ex vivo construct. Collagen is the main component of the 
extracellular matrix,[20] possesses cell adhesion domains for axonal growth,[21] and collagen 
products are employed as medical sealants in neurosurgery for dural repair (e.g. 
Duragen®)[22], justifying its use. 
 
NSCs can be safely labelled with Lumirem;[23] indeed, siloxane coated MNPs are safe for 
clinical MRI in humans[24] and we detected no obvious effect on cOMC health post-labelling 
suggesting protocol safety. Effective labelling was achieved without potentially cytotoxic 
uptake-enhancing strategies (e.g. transfection agents or electroporation), likely due to the high 
endocytotic activity of cOMCs resulting in avid MNP uptake.[18] These cells therefore appear 
well suited for the combined encapsulation and non-invasive imaging approach described here, 
highlighting its potential for clinical cell therapy. However, there are well-known issues in the 
field of cell tracking in terms of MNP labelling and non-invasive imaging. One of these is 
transplant cell death and release of the tracking agents which are subsequently taken up by 
host macrophages, leading to false positives.[16] Implantation of cells within a biomaterial 
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matrix has been shown to improve cell survival and also provides a protective matrix to the 
encapsulated cells.[10,13] Therefore, there may be advantages of using our technique in terms of 
maintaining cell survival and reducing false-positives arising from transplant cell death. 
However, as yet, this is still speculative and would need to be tested in in vivo studies. 
 
At both gel densities used, cell numbers were greatest at the base of the gel, indicating some 
degree of cell sinkage. From a translational standpoint, it is unclear what the significance of 
these “bottom-heavy” constructs could be. Indeed, it may be of some value to know where in 
the construct the highest numbers of cells are, such that if one region of a heterogeneous 
lesion was “more damaged”, the gel could be orientated accordingly. Conversely, this may be 
undesirable in terms of achieving even distribution, in which case there may be some value to 
investigating means of preventing cell collection at the base, such as inverting the well plates 
more frequently during gelation through the development of robotically-assisted automation 
systems, or simply removing the base of the gel pre-implantation. 
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Supporting Information is available from the Wiley Online Library or from the author. 
 
Supplementary Video 1: Z-stack of double labelled cOMCs within a 2.4 mg/ml collagen gel 
at 4 days in vitro, stained with Hoescht and p75. 
Supplementary Video 2: Z-stack of nuclear labelled cOMCs within a 1.2 mg/ml collagen gel 
at 4 days in vitro. 
Supplementary Video 3: Z-stack of LIVE/DEAD stained cOMCs within a 1.2 mg/ml 
collagen gel at 4 days in vitro. 
Supplementary Video 4: Z-stack of LIVE/DEAD stained cOMCs within a 2.4 mg/ml 
collagen gel at 4 days in vitro. 
Supplementary Video 5: Z-stack of magnetic nanoparticle labelled cOMCs stained with 
Perl’s within a 2.4 mg/ml collagen gel at 2 days in vitro. 
Supplementary Video 6: Coronal MRI sections of collagen hydrogels containing (1) 
unlabeled cOMCs and (2) magnetic nanoparticle labelled cOMCs from “sample 1”. 
Supplementary Video 7: Coronal MRI sections of collagen hydrogels containing (1) 
unlabeled cOMCs and (2) magnetic nanoparticle labelled cOMCs from “sample 2”. 
Supplementary Video 8: Coronal MRI sections of collagen hydrogels containing (1) 
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Figure 1 cOMCs were successfully cultured within collagen hydrogels. (A) Representative 
phase image of cOMCs cultured on glass. (B) Representative double-merged fluorescent 
images of p75 positive, bipolar cells (OECs) and Fn positive, rounded cells (fibroblasts) 
(inset; 10 µm scale bar) on glass. Representative fluorescence images of cOECs, 4d within a 
(C) 1.2 mg/mL and (D) 2.4 mg/mL collagen gel. The majority of cells are p75 positive, 
although unstained cells were identified (arrows). Graphs showing the number of cells 
counted at each regularly spaced PoA throughout (E) 1.2 mg/mL and (F) 2.4 mg/mL collagen 
gels. *P<0.05, **P<0.01 and ****P<0.0001 versus PoA1, n=3. 
 
Figure 2 cOMCs survive and proliferate in 3-D culture. (A) Representative z-stack images 
(75, 105 and 135 µm above gel base) showing LIVE (green) and DEAD (red; arrows) cell 
staining within a 2.4 mg/mL collagen gel. (B) Representative double-merged 
(phase/fluorescence) image of EDU positive cOMCs within a 1.2 mg/mL collagen gel. Bar 
charts displaying proportions of (C) LIVE cells and (D) proliferating cells in each 
experimental condition (n=3). 
 
Figure 3 cOMCs were safely labelled with MNPs and visualised in hydrogels using 
histology and MRI. Representative Perl’s and neutral red staining of (A) unlabelled cOMCs 
and (B) Lumirem labelled cOMCs on glass. Bar charts depicting quantification of (C) cell 
number and (D) cell viability in unlabelled and labelled samples (n=3). (E) Representative 
light microscopy images of Perl’s stained hydrogel containing labelled cOMCs taken at the 
(E) base and (E-inset) middle of the gel. (F) Representative MRI coronal sections of collagen 
hydrogels from individual dog samples containing (top) unlabelled cOMCs and (bottom) 
MNP labelled cOMCs. 
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Injection of cell suspensions for clinical transplantation results in cell death, washout 
and uneven distribution. To address this, we show canine olfactory mucosal cells can be 
propagated safely throughout implantable, protective collagen matrices. In addition, we show 
biomaterial encapsulation of clinical transplant populations can be combined with 
nanoparticle imaging technologies to non-invasively visualize intraconstruct cell populations 
using magnetic resonance imaging.  
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